R-CDOP regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of rituximab, cyclophosphamide, liposomal doxorubicin|doxorubic..." |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[cyclophosphamide]], liposomal [[doxorubicin|doxorubicin (Caelyx)]], [[vincristine]], [[prednisone]] used to treat [[non-Hodgkin lymphoma]].<ref name="pmid12161358">{{cite journal| author=Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP et al.| title=Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. | journal=Haematologica | year= 2002 | volume= 87 | issue= 8 | pages= 822-7 | pmid=12161358 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12161358 }} </ref> | {{PAGENAME}} refers to a regimen consisting of [[rituximab]], [[cyclophosphamide]], liposomal [[doxorubicin|doxorubicin (Caelyx)]], [[vincristine]], [[prednisone]] used to treat [[non-Hodgkin lymphoma]].<ref name="pmid12161358">{{cite journal| author=Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP et al.| title=Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. | journal=Haematologica | year= 2002 | volume= 87 | issue= 8 | pages= 822-7 | pmid=12161358 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12161358 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|D|Doxorubicin (Caelyx)}} | {{chemo|D|Doxorubicin (Caelyx)}} | ||
{{chemo|O|Vincristine (Oncovin)}} | {{chemo|O|Vincristine (Oncovin)}} | ||
| Line 15: | Line 17: | ||
==Indications== | ==Indications== | ||
*[[Non-Hodgkin lymphoma]].<ref name="pmid12161358">{{cite journal| author=Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP et al.| title=Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. | journal=Haematologica | year= 2002 | volume= 87 | issue= 8 | pages= 822-7 | pmid=12161358 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12161358 }} </ref> | *[[Non-Hodgkin lymphoma]].<ref name="pmid12161358">{{cite journal| author=Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP et al.| title=Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. | journal=Haematologica | year= 2002 | volume= 87 | issue= 8 | pages= 822-7 | pmid=12161358 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12161358 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | |||
[[Category:Chemotherapy regimens]] | |||
Latest revision as of 20:12, 27 March 2015
|
WikiDoc Resources for R-CDOP regimen |
|
Articles |
|---|
|
Most recent articles on R-CDOP regimen Most cited articles on R-CDOP regimen |
|
Media |
|
Powerpoint slides on R-CDOP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-CDOP regimen at Clinical Trials.gov Trial results on R-CDOP regimen Clinical Trials on R-CDOP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-CDOP regimen NICE Guidance on R-CDOP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-CDOP regimen Discussion groups on R-CDOP regimen Patient Handouts on R-CDOP regimen Directions to Hospitals Treating R-CDOP regimen Risk calculators and risk factors for R-CDOP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-CDOP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
R-CDOP regimen refers to a regimen consisting of rituximab, cyclophosphamide, liposomal doxorubicin (Caelyx), vincristine, prednisone used to treat non-Hodgkin lymphoma.[1]
Regimen
RRituximab
CCyclophosphamide
DDoxorubicin (Caelyx)
OVincristine (Oncovin)
PPrednisone
Indications
References
- ↑ 1.0 1.1 Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP; et al. (2002). "Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study". Haematologica. 87 (8): 822–7. PMID 12161358.